

# NATURAL AGENTS IN THE MODULATION OF METABOLIC SYNDROME

Fauzia Bano, Seema Kanojia, Arvind K. Srivastava

*Department of Food and Nutrition*

Era University, Sarfarazganj, Hardoi Road, Lucknow, U.P., India-226003.

Received on : 23-12-2023

Accepted on : 02-07-2024

## ABSTRACT

Metabolic syndrome or syndrome X is a profound health issue across the world and a recognized risk elements for both atherosclerosis-related as well as non-atherosclerotic cardiovascular disease. There was remarkable variation in the definition and diagnostic parameters for metabolic syndrome, which represents a chronological advancement in perception about this ailment. Several triggers leading to the primary cause of persistent inflammation variables for metabolic syndrome are pathophysiological. Finding a reliable alternative medication that is ecological and spared from adverse effects, therefore will be a helpful tool in the battle counter to metabolic syndrome. In this set of circumstances, consuming functional foods or making the supposition that natural bioactive compounds (NBCs) exist might have an advantageous effect on controlling body mass, glucose metabolism, and hypertension, as well as endothelial destruction, enhancing lipid profiles, reducing inflammation, and reducing oxidative stress. NBCs like EGCG, curcumin, polyphenols, allicin, barberine, quercetin, hydroxytyrosol, resveratrol etc. shows activity against the risk factors for metabolic syndrome. This review emphasizes the latent activities of NBCs in the modulation of metabolic syndrome, its associates risk determinants, as well as in their prevention.

**KEYWORDS:** Metabolic Syndrome, Natural bioactive agents, Obesity, Insulin Resistance, Dyslipidemia, Cardiovascular diseases.

## INTRODUCTION

The incidence of chronic degenerative non-communicable diseases (CDNCDs) has increase drastically during the past century. This is due to the population's average life expectancy increasing as well as the proliferation of risk factors for unhealthy lifestyles like smoking, drinking too much alcohol, being sedentary, and having poor dietary habits. The metabolic syndrome, one of the most prominent CDNCDs [1].

Obesity, hypercholesterolemia, or insulin resistance all are contributory factors to the metabolic syndrome. It begins by identifying individuals who have a higher vulnerability to acquiring type 2 diabetes mellitus and atherosclerotic CVD. Secondly, by considering the interrelationships among the different elements of the metabolic syndrome, we may be able to comprehending the pathophysiology integrating them to the increased probability of heart disease. Thirdly, it contributes to making it more feasible to conduct epidemiological and clinical research on pharmacological, dietary, and preventative treatment methods [2]. It's crucial to correctly diagnose patients

so that lifestyle and risk factor modifications can be made to improve the disease's outcomes. Metabolic syndrome can be diagnosed whether one or more of its symptoms like abdominal visceral fat, hypertension, impaired insulin sensitivity, and hypercholesterolemia are present [3].

**Epidemiology of Metabolic Syndrome:** Metabolic syndrome is a worldwide issue. Abdominal obesity is allied with the higher probability of metabolic syndrome. Based on several variables, such as gender, ethnic group, age and the criteria used for diagnosis, the disease's prevalence differs throughout various nations and locations. As people age, their risk of developing metabolic syndrome rises. Less than 10% of young adults in their 20s and 40% of seniors in their 60s are affected by metabolic syndrome. The condition can affect schoolchildren, and some of them may even possess more than two of its symptoms (central obesity, insulin resistance, hypertension and dyslipidemia). More than 45 million adult Americans, or more than one-fifth of the population, are affected by metabolic syndrome in the US [4]. Depend upon global epidemiological studies, the frequency rate of metabolic syndrome is approximately estimated in

## Address for correspondence

**Dr. Arvind Kumar Srivastava**

Department of Food and Nutrition

Era University, Sarfarazganj, Hardoi Road,

Lucknow, U.P., India-226003.

Email: drarv55cdri@rediffmail.com

Contact no: +91-9415005598



between 20% and 45%, with a roughly increment of 53% by 2035.

**Pathophysiology of Syndrome X or Metabolic Syndrome:** Abdominal obesity and insulin resistance have been identified as the primary pathophysiologic abnormalities underlying the metabolic syndrome. Since these two risk factors are intricately linked to one another, it is impossible to say which is more important for Metabolic Syndrome etiology and progression. Furthermore, contributing factors like age, ethnicity/race, food, physical inactivity, dysregulation of cytokines originating from adipose tissue, genetics, inflammation, abnormalities in hormone levels, and medications further complicate the pathophysiology of metabolic syndrome [5].

An increased concentration of the adipose tissue in abdominal area has been related to an elevated incidence of insulin resistance, T2DM, and CVD. [6, 7]. Endocrine roles of adipose tissue, is further categorized into two kinds of adipose tissue i.e. brown adipose tissue and white adipose tissue, regulates a number of metabolic pathways that, if changed, might result in a dysfunctional glucose and lipid metabolism [8]. Protein 4 (FABP4) that binds fatty acids, adiponectin, leptin, hydroxyl fatty acids (FAHFs) that are ester of fatty acids and palmitoleate are other substances secreted by WAT that have an impact on the hepatic tissue, skeletal muscles, brain, and pancreas. Because it facilitates the emission of cytokines that are associated with inflammation in the blood, which involve interleukin-6, interleukin-8, and tumor necrosis factor- $\alpha$ , only the previous one is associated with the cardiovascular morbidity, [8, 9,10]. In fact, IR, T2DM, metabolic, and CV disorders can be spurred on by the pro-inflammatory chemicals secreted from adipose tissue [11-12]. Many researches have indicated that some cytokines that caused inflammation, such as interleukin-1 and interleukin-18, are present in metabolic syndrome and are crucial for the advancement of the atheromatous plaques.

The pathophysiology of metabolic syndrome is significantly influenced by elevated concentration of mono and diacylglycerols in the blood, caused by insulin resistance. Insulin inhibits hepatic gluconeogenesis and lipolysis while elevating the absorption of glucose in muscle and the liver. However, adipose tissue has impaired insulin's capacity to conquer lipolysis during impaired insulin sensitivity, which leads to the transmission of free fatty acid levels to rise and stimulate to reduce antilipolytic effect of insulin [13]. Protein kinase is not activated by the muscle due to the presence of FFAs, which results

in the less absorption of glucose. They enhance the liver's ability to activate protein kinase, which promotes the gluconeogenesis and lipogenesis. In order to maintain euglycemia, a hyper-insulinemic condition is created overall. The compensation eventually fails, and insulin secretion declines. The pancreas' beta cells are likewise lipotoxic to FFAs, which results in less insulin production.

Accelerated action of sympathetic nervous system (SNS), and the salt reabsorption in the kidneys are additional processes. Because insulin resistance raises serum viscosity, it increases the risk of CVD, inducing a prothrombotic condition, and activating a pro-inflammatory cytokine from adipose tissue [14]. An increase levels of FFAs result in more production of apolipoprotein B by the liver, as well as increase synthesis of triglyceride. The lowering in HDL-cholesterol and intensify in low density lipoprotein-cholesterol are the indirect consequences of changes in the lipid metabolism in liver [15].

**Research Methodology:** The electronic databases Pubmed, Scopus, Google Scholar were searched for the paper (original or review papers) through August 2023. The terms "metabolic syndrome," "natural bioactive compounds," "metabolic changes," "endothelial destruction," "lipid profile," "inflammation," "oxidative stress," "polyphenols" and "alternative medicine" were used. Additionally, we only incorporated English-language papers. Each and every reference were manually selected for the article.

### Potential effect of Natural Agents or Bioactive Compounds in modulation of the Metabolic Syndrome

The initial therapeutic strategy implemented in the case of metabolic syndrome is dietary and lifestyle advancement. The therapeutic management of metabolic syndrome comorbidities can actually be aided by a better dietary regime, including a decrease in caloric consumption in cases of overweight and obesity, also a decrease in salt, saturated fats, cholesterol, and simple carbohydrates [16]. Other associated factors of metabolic syndrome can be regulated by the dietary modifications; for example, dyslipidemia, hyperglycaemia, and hypertension have been identified to be improved by a minimal consumption of sodium, cholesterol, saturated fatty acids, and simple carbohydrates. Diets with a excessive and a very low-fat substance aggravate atherogenic dyslipidemia; as a result, it's typically advised to consume 25–35% of daily calories as fat.

Metabolic syndrome does not have a single medication that is effective, and the polypharmacy and low




compliance that result from the present pharmacotherapy and related comorbidities make it difficult for patients to take multiple medications for a prolonged duration. Since their impact is unknown what the long-term cardiovascular results and compliance will be, considerable concern in using the naturally available bioactive compounds to decrease the vulnerability and progression of the metabolic syndrome.

Natural bioactive agents have been shown positive impact on managing obesity and a decrease in visceral obesity in various clinical investigations. Catechins and its derivatives are among of the most extensively researched bioactive compounds for their potential anti-obesity activity. As it turns out, these bioactive molecules appear to have two main ways of reducing body weight: raising energy expenditure by activating the sympathetic nervous system, which enhances lipid oxidation, especially in adipose tissue; and lowering intestinal lipid

content, which helps people consume less calories [18].

Epigallocatechin gallate (EGCG) is a natural biologically active agent abundantly occur in a green tea. According to an array of clinical studies [19-22], EGCG consumption is linked to a remarkable decrease in abdominal obesity, BMI, and intra-abdominal fat. These activities have frequently been investigated in relation to caffeine use, which appears to work in combination with EGCG to reduce body weight [23]. It seems that EGCG can increase AMPK activity. AMP-activated protein kinase (AMPK) contributes to decreased fat production, increased fat breakdown, and improved insulin sensitivity, all of which leads to reduced body weight. Coffee contains a significant amount of chlorogenic acid, which appears to work by modulating the PPAR, the receptor in charge of lipid metabolism, it can also help intercept the buildup of visceral fat and uncontrolled body weight [24, 25].



**Fig. 1: The Impact of Naturally Occurring Bioactive agents on the Metabolic Syndrome**



MUFAs, PUFAs, fibre, folate, calcium, magnesium, and potassium are all present in nuts, making them useful foods. Their impact on body weight management appears to be brought about by a rise in satiety [26-28].

In addition, nuts are an excellent food source for managing metabolic syndrome because they have a favorable impact on the modulation of lipid and glucose metabolism [29]. Further research has determined the role the curcumin, the naturally occurring phenol found in *Curcuma longa*, plays an important role in managing pathways related with obesity. In addition to the low-calorie diet, curcumin use accelerates weight loss, resulting in decreased

FM%, BMI, and body circumferences. [30-32].

Turmeric, one of the NBCs, that have been constantly investigated for its anti-inflammatory, anti-diabetic and antioxidant characteristics, and it come into sight to have a significant regulatory role on diabetes and insulin resistance. Curcumin is one of the important natural bioactive agents that shows anti-inflammatory, antioxidant and have modulatory activities on T2DM and insulin resistance [33, 34]. Additionally, the anti-inflammatory and anti-lipolytic activities of its antihyperglycemic role have been linked to a decrease in circulation of fatty free acids (FFAs) levels and TNF- $\alpha$ , respectively [35-37].

Natural Bioactive Compounds	Source	Pathways	References
EGCG (Epigallocatechin gallate)	Green Tea ( <i>Camellia sinensis</i> )	↑ Enhance AMPK activity ↓ Body Weight, BMI and Visceral fat	21, 22
Curcumin	<i>Curcuma longa</i>	↓ Adipocytes differentiation ↑ Preadipocytes apoptosis ↓ Body Weight, BMI and Waist Hip Ratio Anti-inflammatory, antioxidant ↓ Leptin, ↑ adiponectin ↑ Insulin sensitivity, ↓ Obesity	32, 63, 64
Polyphenols	Cinnamon ( <i>Cinnamomum zeylanicum</i> )	Antithrombotic activity, Anti-inflammatory, ↑ Insulin sensitivity ↑ GLUT4 ↓ Blood Glucose, Fasting blood sugar, HbA1c ↓ PP glucose levels ↑ Insulin sensitivity TRPA1 activation ↑ Vasorelaxation ↓ GSK3 $\beta$ Activating PPAR $\gamma$ and PPAR $\alpha$	65, 66-68
Allicin	Garlic ( <i>Allium sativum</i> )	Increase Anti-inflammatory and Antioxidant activities, Decrease Hypercholesteremia and Triglycerides levels and increase Adiponectin levels	39, 70
Barberine	<i>Rhizoma coptidis</i>	Increase Insulin sensitivity, decrease Systolic blood pressure, ↓ Body weight and Triglycerides	47
Quercetin	Onions ( <i>Allium cepa</i> ), Grapes, Red wine	↓ Adipogenesis ↑ Lipolysis ↓ Blood glucose, ↓ cholesterol levels Modulation of PPAR $\gamma$ increases the activity of AMPK ↓ Obesity ↑ GSH synthesis Catalase, and increase GSH peroxidase modulation of SOD activities Decrease Inflammation	56,71
Olive Oil (Extra Virgin)	Olive ( <i>Olea europaea</i> )	Increase activity of eNOS Increase synthesis of NO and NF- $\kappa$ B Decrease Oxidative Stress and Endothelial damage Decrease Blood Pressure	72-75,45, 76, 77
Hydroxytyrosol		Decrease activity of Nrf2 Decrease synthesis of TNF- $\alpha$ Reduced activity of COX-2 & COX-1 and OS Decrease inflammation	

Table 1: Natural Bioactive Compound in the modulation of Metabolic Syndrome



Oleocanthal		Reduce synthesis of interleukin-6 and interleukin-1 $\beta$ and decrease activity of NF- $\kappa$ B Decrease Inflammation and oxidative stress Decrease COX-2 and iNOS	
Gingerols, Shogaols, Parasols	Ginger ( <i>Zingiber officinale</i> )	Increase anti-inflammatory activities Reduce Cyclooxygenase-2, and 5-lipoxygenase activity Decrease systolic blood pressure Increase activity of AMPK and NF- $\kappa$ B modulation Reduce Endothelial damage and BP	78-80
Resveratrol	Grapes ( <i>Vitis vinifera</i> )	↓ Adipogenesis ↑ Lipolysis ↓ Insulin resistance, ↓ Body mass index Increase activation of SIRT1 and AMPK Decrease activity of $\alpha$ -glucosidase ↑ GLUT4 ↑ PKG1 $\alpha$ activity PPAR $\gamma$ modulation ↓ Adipokines synthesis ↓ Inflammation ↑ PKG1 $\alpha$ activity ↓ OS ↓ BP	81-83, 54, 84-85
Charantin	Bitter gourd ( <i>Momordica charantia</i> )	↓ Blood Glucose level ↓ Serum Cholesterol levels	89, 90
Swertiamarin	Chota-chiretta ( <i>Enicostemma littorale</i> )	↓ Fasting blood glucose, HbA1c, ↓ TC, LDL, triglycerides ↑ Plasma insulin, HDL	91, 92
Gymnemic acid	Gurmar ( <i>Gymnema sylvestre</i> )	↑ MIN 6 ↓ Hyperglycemic effect	93, 94
Garcinol, Hydroxycitric acid, Anthocyanins	Kokum ( <i>Garcinia indica</i> )	Antidiabetic effect, Cardioprotective effect, Anti-obesity activity ↑ SREBP1c, SREBP2c	95
Tannins, Flavonoids, Proanthocyanidin	Rose mallow ( <i>Hibiscus rosasinensis</i> )	↑ Ratio of TC/HDL ↑ Ratio of LDL/HDL Anti-diabetic activity	96
Gallic acid, Ellagic acid, Emblicanin A & B	Amla ( <i>Embolica officinalis</i> )	Cardio protective activity ↓ ChREBP expression ↓ FAS and HMGCR	97-98

**Cont. Table 1: Natural Bioactive Compound in the modulation of Metabolic Syndrome**

Another bioactive compound, Allicin which is found in garlic (*Allium sativum*), have medicinal properties as it possesses antioxidant and antithrombotic properties. Different studies shows that garlic improves insulin sensitivity and also lowers total cholesterol and triglyceride levels [38, 39]. Berries like strawberries, red fruits, blackberries, blueberries, or raspberries contain natural bioactive agents, including anthocyanins and flavonoids [40]. Since lipotoxicity is reduced, it would seem that anthocyanins are responsible for their hypoglycemic activities.

However, anthocyanins function by activating AMPK, which increases the amount of GLUT4 transporters, increases the absorption of glucose, and inhibits gluconeogenesis. In addition, PPAR, CPT1A (carnitine palmitoyltransferase-1A) and acyl-coA oxidase are the genes that modulate the hepatic lipid metabolism by the influence of AMPK [41-42]. Additionally, it appears that anthocyanins stimulate the secretion of the GLP-1, which in turn stimulates the release of insulin.

Olives are abundant in natural polyphenolic substances like as oleuropein, hydroxytyrosol, and tyrosol, which



have a number of beneficial properties. Extra virgin olive oil (EVOO) has been recently gained a scientific attention, as it contains free radical scavenging quality and anti-inflammatory characteristics. The anti-inflammatory and antioxidant qualities of the polyphenols hydroxytyrosol and oleocanthal aid in delaying the onset of chronic degenerative non-communicable diseases (CDNCDs). The stimulation of Nrf2, a factor contributing in the production of phase two enzymes which are involved in detoxification, is one way by which hydroxytyrosol might appear to execute the body's endogenous defences [43]. Both in vivo and in vitro investigations have demonstrated that hydroxytyrosol suppresses the activity of cyclooxygenases (COX)-2 and increases the generation of cytokines that promote inflammation, including TNF- $\alpha$  [44]. Oleocanthal exhibited a primary anti-inflammatory effect comparable to that of ibuprofen (an anti-inflammatory medication) because of its capacity to prevent the activation of COX-1 and COX-2 enzymes, which in turn contributes to the production of inflammatory prostaglandins in a dose-related approach. Preadipocytes expression of genes linked to inflammation can be altered by oleocanthal. As a matter of fact, the research contends that

oleocanthal appears to reduce NF- $\kappa$ B activation, which reacts to incendiary response and controls the synthesis of cytokines and adipokines [45, 46]. By the regulation inflammatory reactions at the adipose tissue level, as suggested by this research, oleocanthal may be able to reduce the persistent low-level inflammatory condition of obesity-related illnesses and metabolic syndrome.

The plant *Rhizoma coptidis* Insulin sensitivity, lipid levels, and body weight all improve when berberine is administered. Equivalent to thiazolidinediones and metformin, berberine acts by downregulating lipogenesis-related genes and activating genes involved in energy utilisation. Berberine also has an insulin-sensitizing effect that is mediated through adipocyte pivoting of the adenosine monophosphate-associated protein kinase. Research on humans with metabolic syndrome has demonstrated a decrease in lipid levels, waist circumference, together with systolic blood pressure, particularly in females [47-49].

Quercetin being demonstrated to have an anti-inflammatory and free radical scavenging characteristics [50-51]. 60 participants in an in vivo trial found that an 8-week treatment of 500 mg/day of quercetin substantial reduced levels of IL6 and C-reactive protein (CRP).




Fig. 2: Structure of Bioactive compound in the modulation of Metabolic Syndrome



Additionally, quercetin appears to decrease the gene expression for inducible nitric oxide synthase (iNOS) and COX-2 [52]. Quercetin may strengthen the body's barriers system against free radicals by encouraging the production of glutathione (GSH), regulating the catalase gene expression, superoxide dismutase (SOD), and GSH peroxidase [53].

A polyphenol, resveratrol (3,5,4'-trihydroxystilbene), is derived from natural herbs notably in grapes, dry fruits or nuts as well as its derivatives like wine. It is a sirtuin pathway activator, that controls a number of cellular processes including metabolism, oxidation, along with aging. It has benefit in reducing adipogenesis and promoting lipolysis via a variety of methods and also prevents cyclooxygenase, with the resulting antioxidant activity [54]. Investigations on individuals suffering from NAFLD and IR have produced encouraging findings [55]. In fact, the investigations on the application of resveratrol in individuals with metabolic syndrome has revealed that it increases insulin sensitivity, glucose tolerance, total weight, and body mass index. Additionally, resveratrol has antioxidant properties that counteract reactive oxygen and nitrogen species [56-57].

Numerous epidemiological studies have looked closely at omega-3 polyunsaturated fatty acids (PUFAs), especially in regards to their preventive impact on metabolic syndrome-related symptoms [58]. Eicosapentaenoic acid and docosahexaenoic acid are two particular PUFAs that are rich in fish oils and have drawn a lot of attention, leading to important preventive recommendations for society [59].

Sulforaphane is another phytochemical that comes from the Brassica family, which includes broccoli. Because of its antioxidant and anti-inflammatory qualities, it has been shown to offer potential therapeutic benefits for metabolic syndrome. It has been demonstrated to offer protection against a range of illnesses, conditions like type 2 diabetes mellitus, hyperlipidemia, and hypertension—each of which is significant contributory factors for the metabolic syndrome [60-62].

### **The relevance of the polyherbal formulation's application in Metabolic Syndrome:**

Approximately 80% of Asians, based upon estimates from the World Health Organization (WHO), receive their primary medical care from complementary and alternative medicine., partly due to the fact that the majority of population in developing countries can hardly afford basic health services. Metabolic syndrome has numerous etiologies; hence no single therapy can reverse the condition. Lifestyle modifications are the core component of risk-adverse persons' prevention and management.

Those with high levels of risk determinanats, on the other hand, are the recipients of pharmaceutical treatment directed at managing individual symptoms [86].

The underlying mechanisms that allow for the synergistic therapeutic effect of polyherbal formulations include the modulation of the different targets or same targets in different mechanisms, which when combined increase activities; the modulation of transporters and enzymes to enhance the bioavailability of oral drugs; neutralization of detrimental effects; and the circumvention of drug resistance mechanisms [87]. Multiple chemical constituents in only one herb or in combination with other herbs exhibit synergism, suggesting that these constituents may be useful as therapeutics for a range of disease targets. This is thought to be more logical and effective in treating diseases with multiple targets and serves as the foundation for polyherbal therapy [88].

### **CONCLUSION**

As a consequence of stress, the synthesis of superoxides, abnormalities in lipid metabolism, and rises in impaired insulin sensitivity, the intricate nature of the metabolic syndrome is becoming more and more pronounced every day. The primary form of treatment and prevention for metabolic syndrome is regarded as changing one's lifestyle worldwide because pharmaceutical therapy is not a complete solution.

It is unquestionably obvious that natural bioactive agents play a beneficial contribution in the medical oversight of syndrome X and its associated concomitant conditions. In actuality, their hypothesis presents a number of positive outcomes, particularly over a long period of time, including body weight management, improved carbohydrate and lipid metabolisms, blood pressure management, endothelium protection, and eventually the reduction in oxidative stress and a persistent low-grade inflammatory state. Even though the possible advantages to health of several natural bioactive agents which have been already received extensive research, more clinical studies with larger population are still required to fully understand the unique mechanisms of action that can be used to regulate metabolic pathways. In order to achieve the positive benefits outlined in the research, it is required to develop worldwide norms for a natural bioactive compound's minimum effective dose and their period of assumption.

**Acknowledgements:** We want to express our sincere appreciation to all the co-authors for their assistance and input. This project received UGC- JRF (University Grant Commission – Junior Research Fellowship), New Delhi, India.



## REFERENCES

- Peters R, Ee N, Peters J, et al. Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction. *Ther Adv Chronic Dis.* 2019; 10: 2040622319880392.
- Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech.* 2009; 2(5-6):231-237.
- Ahmed M, Kumari N, Mirgani Z, et al. Metabolic syndrome; Definition, pathogenesis, Elements, and the Effects of medicinal plants on it's elements. *J Diabetes Metab Disord.* 2022; 21(1): 1011-1022.
- Consultation, W.H.O.; 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Available from: [https://www.staff.ncl.ac.uk/philip.home/who\\_dmc.htm](https://www.staff.ncl.ac.uk/philip.home/who_dmc.htm).
- Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. *J Biol Chem.* 2003; 278(12): 10297-10303.
- Blüher M. Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? *Clin Sci. (Lond).* 2016; 130(18): 1603-1614.
- Mohamed EI, Maiolo C, Iacopino L, et al. The impact of body-weight components on forced spirometry in healthy Italians. *Lung.* 2002; 180(3): 149-159.
- Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. *Nat Rev Endocrinol.* 2019; 15(9): 507-524.
- Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. *Am J Clin Nutr.* 2007; 85(5): 1197-1202.
- Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. *Atherosclerosis.* 2014; 233(1): 104-112.
- Barnard SA, Pieters M, De Lange Z. The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels. *Blood Rev.* 2016; 30(6): 421-429.
- Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. *J Clin Invest.* 2017; 127(1): 1-4.
- Varghese JF, Patel R, Yadav UCS. Novel insights in the metabolic syndrome-induced oxidative stress and inflammation-mediated atherosclerosis. *Curr Cardiol Rev.* 2018; 14(1): 4-14.
- Noce A, Fabrini R, Dessì M, et al. Erythrocyte glutathione transferase activity: a possible early biomarker for blood toxicity in uremic diabetic patients. *Acta Diabetol.* 2014; 51(2): 219-224.
- Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and  $\beta$ -cell dysfunction. *Eur J Clin Invest.* 2002; 32; 3:14-23.
- Juhan-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. *J Thromb Haemost.* 2003; 1(7): 1575-1579.
- Rochlani Y, Pothineni NV, Kovelamudi S, et al. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Ther Adv Cardiovasc Dis.* 2017; 11(8): 215-225.
- Di Daniele N, Marrone G, Di Lauro M, et al. Effects of caloric restriction diet on arterial hypertension and endothelial dysfunction. *Nutrients.* 2021;13(1):274.
- Rains TM, Agarwal S, Maki KC. Antiobesity effects of green tea catechins: a mechanistic review. *J Nutr Biochem.* 2011; 22(1): 1-7.
- Huang J, Wang Y, Xie Z, et al. The anti-obesity effects of green tea in human intervention and basic molecular studies. *Eur J Clin Nutr.* 2014; 68(10): 1075-1087.
- Hibi M, Takase H, Iwasaki M, et al. Efficacy of tea catechin-rich beverages to reduce abdominal adiposity and metabolic syndrome risks in obese and overweight subjects: a pooled analysis of 6 human trials. *Nutr Res.* 2018; 55: 1-10.
- Huang LH, Liu CY, Wang LY, et al. Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial. *BMC Complement Altern Med.* 2018; 18(1): 294.
- Mielgo-Ayuso J, Barrenechea L, Alcorta P, et al. Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy



- homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial. *Br J Nutr.* 2014;111(7):1263-1271.
24. Chen IJ, Liu CY, Chiu JP, et al. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. *Clin Nutr.* 2016; 35(3): 592-599.
25. Hursel R, Viechtbauer W, Dulloo AG, et al. The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis. *Obes Rev.* 2011; 12(7): e573-e581.
26. Watanabe T, Kobayashi S, Yamaguchi T, et al. Coffee abundant in chlorogenic acids reduces abdominal fat in overweight adults: A randomized, double-blind, controlled trial. *Nutrients.* 2019; 11(7): 1617.
27. Zhong Y, Ding Y, Li L, et al. Effects and mechanism of chlorogenic acid on weight loss. *Curr Pharm Biotechnol.* 2020; 21(11): 1099-1106.
28. Noce A, Marrone G, Di Daniele F, et al. Potential cardiovascular and metabolic beneficial effects of  $\omega$ -3 PUFA in male obesity secondary hypogonadism syndrome. *Nutrients.* 2020; 12(9): 2519.
29. Dessì M, Noce A, Bertucci P, et al. Plasma and erythrocyte membrane phospholipids and fatty acids in Italian general population and hemodialysis patients. *Lipids Health Dis.* 2014; 13(1): 54.
30. Cassady BA, Hollis JH, Fulford AD, et al. Mastication of almonds: effects of lipid bioaccessibility, appetite, and hormone response. *Am J Clin Nutr.* 2009; 89(3): 794-800.
31. Konstantinidi M, Koutelidakis AE. Functional foods and bioactive compounds: a review of its possible role on weight management and obesity's metabolic consequences. *Medicines (Basel).* 2019; 6(3): 94.
32. Di Pierro F, Bressan A, Ranaldi D, et al. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. *Eur Rev Med Pharmacol Sci.* 2015; 19(21): 4195-4202.
33. Mousavi SM, Milajerdi A, Varkaneh HK, et al. The effects of curcumin supplementation on body weight, body mass index and waist circumference: a systematic review and dose-response meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr.* 2020; 60(1): 171-180.
34. Akbari M, Lankarani KB, Tabrizi R, et al. The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. *Front Pharmacol.* 2019; 10: 649.
35. Adibian M, Hodaei H, Nikpayam O, et al. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. *Phytother Res.* 2019; 33(5): 1374-1383.
36. Pivari F, Mingione A, Brasacchio C, et al. Curcumin and type 2 diabetes mellitus: prevention and treatment. *Nutrients.* 2019; 11(8): 1837.
37. El-Moselhy MA, Taye A, Sharkawi SS, et al. The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF- $\alpha$  and free fatty acids. *Food Chem Toxicol.* 2011; 49(5): 1129-1140.
38. Padiya R, Khatua TN, Bagul PK, et al. Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed rats. *Nutr Metab (Lond).* 2011; 8(1): 53.
39. Reinhart KM, Talati R, White CM, et al. The impact of garlic on lipid parameters: a systematic review and meta-analysis. *Nutr Res Rev.* 2009; 22(1): 39-48.
40. Basu A. Role of berry bioactive compounds on lipids and lipoproteins in diabetes and metabolic syndrome. *Nutrients.* 2019; 11(9): 1983.
41. Tsuda T. Recent progress in anti-obesity and anti-diabetes effect of berries. *Antioxidants (Basel).* 2016; 5(2): 13.
42. Takikawa M, Inoue S, Horio F, et al. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. *J Nutr.* 2010; 140(3): 527-533.
43. Bayram B, Ozcelik B, Grimm S, et al. A diet rich in olive oil phenolics reduces oxidative stress in the heart of SAMP8 mice by induction of Nrf2-dependent gene expression. *Rejuvenation Res.* 2012; 15(1): 71-81.
44. Fuccelli R, Fabiani R, Rosignoli P. Hydroxytyrosol exerts anti-inflammatory and anti-oxidant



- activities in a mouse model of systemic inflammation. *Molecules*. 2018; 23(12): 3212.
45. Zhang X, Cao J, Zhong L. Hydroxytyrosol inhibits pro-inflammatory cytokines, iNOS, and COX-2 expression in human monocytic cells. *Naunyn-Schmiedeberg Arch Pharmacol*. 2009; 379(6): 581-586.
  46. Romani A, Ieri F, Urciuoli S, et al. Health effects of phenolic compounds found in extra-virgin olive oil, by-products, and leaf of *Olea europaea* L. *Nutrients*. 2019; 11(8): 1776.
  47. Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. *Evid Based Complement Alternat Med*. 2012; 2012: 363845.
  48. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. *Diabetes*. 2006; 55(8): 2256-2264.
  49. Pérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. *Metab Syndr Relat Disord*. 2013; 11(5): 366-369.
  50. Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. *Nutrients*. 2016; 8(3): 167.
  51. Xu D, Hu MJ, Wang YQ, et al. Antioxidant activities of quercetin and its complexes for medicinal application. *Molecules*. 2019; 24(6): 1123.
  52. Carlsen I, Frøkiær J, Nørregaard R. Quercetin attenuates cyclooxygenase-2 expression in response to acute ureteral obstruction. *Am J Physiol Ren Physiol*. 2015; 308(11): F1297-F1305.
  53. Rivera L, Morón R, Sánchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. *Obesity (Silver Spring)*. 2008; 16(9): 2081-7.
  54. Bremer AA. Resveratrol use in metabolic syndrome. *Metab Syndr Relat Disord*. 2014; 12(10): 493-495.
  55. Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. *Dig Liver Dis*. 2015; 47(3): 226-232.
  56. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. *Pharmacol Res*. 2013; 72: 69-82.
  57. Chaplin A, Carpéné C, Mercader J. Resveratrol, metabolic syndrome, and gut microbiota. *Nutrients*. 2018; 10(11): 1651.
  58. Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not  $\alpha$ -linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr*. 2006; 84(1): 5-17.
  59. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation*. 2006; 114(1): 82-96.
  60. Wu L, Juurlink BH. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. *J Hypertens*. 2001; 19(10): 1819-1825.
  61. de Souza CG, Sattler JA, de Assis AM, et al. Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats. *J Med Food*. 2012; 15(9): 795-801.
  62. Song MY, Kim EK, Moon WS, et al. Sulforaphane protects against cytokine- and streptozotocin-induced  $\beta$ -cell damage by suppressing the NF- $\kappa$ B pathway. *Toxicol Appl Pharmacol*. 2009; 235(1): 57-67.
  63. Wu LY, Chen CW, Chen LK, et al. Curcumin attenuates adipogenesis by inducing preadipocyte apoptosis and inhibiting adipocyte differentiation. *Nutrients*. 2019; 11(10): 2307.
  64. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. *Annu Rev Nutr*. 2010; 30: 173-99.
  65. Ziegenfuss TN, Hofheins JE, Mendel RW, et al. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. *J Int Soc Sports Nutr*. 2006; 3(2): 45-53.
  66. Khan A, Safdar M, Ali Khan MM, et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care*. 2003; 26(12): 3215-3218.



67. Cao H, Polansky MM, Anderson RA. Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. *Arch Biochem Biophys*. 2007; 459(2): 214-222.
68. Beejmohun V, Peytavy-Izard M, Mignon C, et al. Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. *BMC Complement Altern Med*. 2014; 14: 351.
69. Alvarez-Collazo J, Alonso-Carbajo L, López-Medina AI, et al. Cinnamaldehyde inhibits L-type calcium channels in mouse ventricular cardiomyocytes and vascular smooth muscle cells. *Pflugers Arch*. 2014; 466(11): 2089-2099.
70. Gómez-Arbeláez, Lahera D, V Oubiña P, et al. Aged garlic extract improves adiponectin levels in subjects with metabolic syndrome: a double-blind, placebo-controlled, randomized, crossover study. *Mediators Inflamm*. 2013; 2013: 285795.
71. Toledo E, Hu FB, Estruch R, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. *BMC Med*. 2013; 11: 207.
72. Rozati M, Barnett J, Wu D, et al. Cardio-metabolic and immunological impacts of extra virgin olive oil consumption in overweight and obese older adults: a randomized controlled trial. *Nutr Metab (Lond)*. 2015; 12(1): 28.
73. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013; 368(14): 1279-1290.
74. Romani A, Bernini R, Noce A, et al. Potential beneficial effects of extra virgin olive oils characterized by high content in minor polar compounds in nephropathic patients: A pilot study. *Molecules*. 2020; 25(20): 4757.
75. Scotece M, Gómez R, Conde J, et al. Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1 $\alpha$  and IL-6 in J774 macrophages and in ATDC5 chondrocytes. *Life Sci*. 2012; 91(23-24): 1229-1235.
76. Carpi S, Scoditti E, Massaro M, et al. The extra-virgin olive oil polyphenols oleocanthal and oleacein counteract inflammation-related gene and miRNA expression in adipocytes by attenuating NF- $\kappa$ B activation. *Nutrients*. 2019; 11(12): 2855.
77. Hasani H, Arab A, Hadi A, et al. Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials. *Phytother Res*. 2019; 33(6): 1639-1647.
78. Zhu J, Chen H, Song Z, et al. Effects of ginger (*Zingiber officinale* Roscoe) on type 2 diabetes mellitus and components of the metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *Evid Based Complement Alternat Med*. 2018; 2018: 5692962.
79. Li LL, Cui Y, Guo XH, et al. Pharmacokinetics and tissue distribution of gingerols and shogaols from ginger (*Zingiber officinale* rosc.) in rats by UPLC-Q-Exactive-HRMS. *Molecules*. 2019; 24(3): 512.
80. Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. *Diabetes*. 2010; 59(3): 554-63.
81. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. *Cell Metab*. 2012; 15(5): 675-690.
82. Imamura H, Nagayama D, Ishihara N, et al. Resveratrol attenuates triglyceride accumulation associated with upregulation of Sirt1 and lipoprotein lipase in 3T3-L1 adipocytes. *Mol Genet Metab Rep*. 2017; 12: 44-50.
83. Simental-Mendía LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial. *Nutrition*. 2019; 58: 7-10.
84. Fogacci F, Tocci G, Presta V, et al. Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. *Crit Rev Food Sci Nutr*. 2019; 59(10): 1605-1618.
85. Prysyazhna O, Wolhuter K, Switzer C, et al. Blood pressure-lowering by the antioxidant resveratrol is counterintuitively mediated by oxidation of cGMP-dependent protein kinase. *Circulation*. 2019; 140(2): 126-137.
86. Mohamed S. Functional foods against metabolic syndrome (obesity, diabetes, hypertension and dyslipidemia) and cardiovascular disease. *Trends Food Sci Technol*. 2014; 35(2): 114-128.
87. Amin F, Gilani AH, Mehmood MH, et al. Coadministration of black seeds and turmeric shows enhanced efficacy in preventing metabolic



syndrome in fructose-fed rats. *J Cardiovasc Pharmacol.* 2015; 65(2): 176-183.

88. Aziz N, Mehmood MH, Gilani AH. Studies on two polyherbal formulations (ZPTO and ZTO) for comparison of their antidyslipidemic, antihypertensive and endothelial modulating activities. *BMC Complement Altern Med.* 2013; 13(1): 371.
89. Singh N, Gupta M. Regeneration of  $\beta$ -cells in islets of Langerhans of pancreas of alloxan diabetic rats by acetone extract of *Momordica charantia* (Linn.) (bitter gourd) fruits. *Indian J Exp Biol.* 2007; 45: 1055-1062.
90. Singh N, Tyagi SD, Agarwal SC. Effect of long term feeding of acetone extract of *Momordica charantia* (whole plant powder) on alloxan diabetic albino rats. *Indian J Physiol Pharmacol.* 1989; 33(2): 97-100.
91. Ahamad J, Hassan N, Amin S, et al. Swertiamarin contributes to glucose homeostasis via inhibition of carbohydrate metabolizing enzymes. *J Natural Remed.* 2017; 16(4): 125-130.
92. Dhanavathy G. Immunohistochemistry, histopathology and biomarker studies of swertiamarin, a secoiridoid glycoside, prevents and protects streptozotocin-induced  $\beta$ -cell damage in Wistar rat pancreas. *J Endocrinol Invest.* 2015; 38(6): 669-684.
93. Ahamad J, Ameen MSM, Answer ET, et al. A critical review on potential pharmacological and phytochemical properties of *Gymnema sylvestre* RBJ. *Global Trends Pharm Sci.* 2018; 9(3): 5869-5886.
94. Kang MH, Lee MS, Choi MK, et al. Hypoglycemic activity of *Gymnema sylvestre* extracts on oxidative stress and antioxidant status in diabetic rats. *J Agric Food Chem.* 2012; 60(10): 2517-2524.
95. Yamaguchi F, Ariga T, Yoshimura Y, et al. Antioxidative and antiglycation activity of garcinol from *Garcinia indica* fruit rind. *Journal of Agricultural & Food Chemistry.* 2010; 48: 180-185.
96. Sachdewa A, Khemani LD. Effect of *Hibiscus rosasinensis* Linn. ethanol flower extract on blood glucose and lipid profile in streptozotocin induced diabetic in rats. *J Ethnopharmacol.* 2003; 89: 61-66.
97. Jeevangi S., Manjunath S., Sakhare P. M. A study of anti-hyperlipidemia, hypolipidemic and antiatherogenic activity of fruit of *Embolica officinalis*(amla) in high fat fed albino rats. *International Journal of Medical Research & Health Sciences.* 2013; 1(2): 70-77.
98. Baliga MS, Prabhu AN, Prabhu DA, et al. Antidiabetic and Cardioprotective Effects of Amla (*Embolica officinalis*Gaertn) and its Phytochemicals: Preclinical Observations. *Bioactive Food as Dietary Interventions for Diabetes.* 2013; 583-600.



**Orcid ID:**

Fauzia Bano - <https://orcid.org/0000-0003-4718-3804>

Seema Kanojia - <https://orcid.org/0000-0002-6044-3095>

Arvind Kumar Srivastava - <https://orcid.org/0000-0003-2212-2343>

**How to cite this article:**

Bano F., Kanojia S., Srivastava A.K. Natural Agents In The Modulation Of Metabolic Syndrome. *Era J. Med. Res.* 2024; 11(2): 1-12.

**Licensing Information**

Attribution-ShareAlike 2.0 Generic (CC BY-SA 2.0) Derived from the licensing format of creative commons & creative commons may be contacted at <https://creativecommons.org/> for further details.